Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeogenFRA:NG2 +4.86%69 Cash Ratio is 1.17 as of May. 2026, which is 74% below its 10-year median of 4.45. GuruFocus rates FRA:NG2 with a GF Score™ of 69/100 and a GF Value™ of €9.71 (Fairly Valued). The stock has 5 warning signs investors should review. Among 825 Medical Devices & Instruments companies, Neogen ranks better than 55.27% on this metric.
Neogen has a Cash Ratio of 1.17. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Neogen's Cash Ratio or its related term are showing as below:
FRA:NG2'
s Cash Ratio Range Over the Past 10 Years
Min: 0.74 Med: 4.45 Max: 7.11
Current: 1.17
During the past 13 years, Neogen's highest Cash Ratio was 7.11. The lowest was 0.74. And the median was 4.45.
FRA:NG2's Cash Ratio is ranked better than 55.27% of 825
companies
in the Medical Devices & Instruments industry
Industry Median: 0.95
vs FRA:NG2: 1.17
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Neogen Cash Ratio Related Terms
Neogen Cash Ratio Historical Data
* Premium members only.
The historical data trend for Neogen's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NG2 vs NVCR, AXGN, UFPT: Cash Ratio Comparison
For the Medical Devices subindustry, Neogen's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neogen Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Neogen's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Neogen's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neogen (FRA:NG2) has a Cash Ratio of 1.17 as of May. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Neogen and its competitors. This is 74% below median its historical median of 4.45. Over the past decade, Neogen's Cash Ratio has ranged from 0.74 to 7.11. According to the industry distribution chart, Neogen ranks #369 out of 825 companies in the Medical Devices & Instruments industry, placing it in the top 44.7%.
Is Neogen's Cash Ratio too high?
Neogen's current Cash Ratio of 1.17 is 74% below median its 10-year median of 4.45. Over the past 10 years, this metric has ranged from a low of 0.74 to a high of 7.11. The Medical Devices & Instruments industry median Cash Ratio is 0.95. Neogen's value of 1.17 is 23.2% above this industry median. Based on the distribution chart, Neogen ranks #369 out of 825 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Neogen has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neogen's Cash Ratio compare to NVCR and AXGN?
According to the Medical Devices & Instruments industry distribution chart, Neogen ranks #369 out of 825 companies for Cash Ratio. This puts Neogen in the upper half of its industry. The industry median Cash Ratio is 0.95. Neogen's value of 1.17 is 23.2% above this benchmark. Historically, Neogen's own Cash Ratio has ranged from 0.74 to 7.11 over the past decade. While the company's 10-year median is 4.45 vs. the industry median of 0.95, Neogen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.95, based on 825 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neogen's current Cash Ratio of 1.17 is 23.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Neogen and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neogen's current Cash Ratio is 1.17, which is 74% below median its own 10-year median of 4.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neogen stock overvalued right now?
Based on GuruFocus' analysis, Neogen (FRA:NG2) is currently considered Fairly Valued. The stock's GF Value™ is €9.71, compared to a current price of €10.28 — trading 5.9% above its estimated fair value. The current Cash Ratio is 1.17, which is 74% below median its 10-year median of 4.45 and 23.2% above the Medical Devices & Instruments industry median of 0.95. Neogen's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Neogen (FRA:NG2), the current Cash Ratio is 1.17 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neogen (FRA:NG2) Overvalued in 2026?
Based on GuruFocus' analysis, Neogen stock appears to be overvalued.
The current stock price of €10.28 is trading 5.9% above its estimated GF Value™ of €9.71.
GuruFocus considers Neogen to be Fairly Valued.
Key valuation signals for FRA:NG2:
Cash Ratio: 1.17 (74% below median its 10-year median of 4.45)
GF Value™: €9.71 vs. price of €10.28 (5.9% above fair value)
Industry Position: 23.2% above the Medical Devices & Instruments median (#369 of 825)
No single metric tells the full story. See the FRA:NG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
69GF Score
Get the complete analysis for FRA:NG2
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NG2 has been successfully added to your 
